- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma ; volume:12 ; number:3 ; year:2019 ; pages:872-879
Case reports in oncology ; 12, Heft 3 (2019), 872-879
- Urheber
-
Bjursten, Sara
Vannas, Christoffer
Filges, Stefan
Puls, Florian
Pandita, Ankur
Fagman, Henrik
Ståhlberg, Anders
Levin, Max
- DOI
-
10.1159/000504291
- URN
-
urn:nbn:de:101:1-2020011600134526987782
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bjursten, Sara
- Vannas, Christoffer
- Filges, Stefan
- Puls, Florian
- Pandita, Ankur
- Fagman, Henrik
- Ståhlberg, Anders
- Levin, Max
Ähnliche Objekte (12)
Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Apoptoseinduktion durch BRAF, MEK Inhibition in humanen Melanomzellen
MEK + CDK4 a regimen for non-BRAF V6000 melanoma
BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition
SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma
Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Apoptoseinduktion durch BRAF, MEK Inhibition in humanen Melanomzellen
MEK + CDK4 a regimen for non-BRAF V6000 melanoma
BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition
SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma
Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Apoptoseinduktion durch BRAF, MEK Inhibition in humanen Melanomzellen
MEK + CDK4 a regimen for non-BRAF V6000 melanoma
BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition
SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma
Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors